Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05450718 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Low-dose Buprenorphine Initiation for Opioid Use Disorder

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv22
  2. Collaborators expanded, about 6 wordsv21
  3. Primary completion date: Oct 2027 to Mar 17, 2027
    • Study completion date: Nov 2027 to Jun 30, 2027
    • Eligibility criteria revised
    v20
  4. Start date changed from estimate of Nov 2024 to Nov 11, 2024v19
  5. Primary completion date: Sep 2027 to Oct 2027
    • Study completion date: Oct 2027 to Nov 2027
    • Start date: Oct 2024 to Nov 2024
    v18
Show 16 earlier versionsHide 16 earlier versions
  1. Start date: Sep 2024 to Oct 2024v17
  2. Primary completion date: Aug 31, 2027 to Sep 2027
    • Study completion date: Sep 30, 2027 to Oct 2027
    • Start date: Aug 20, 2024 to Sep 2024
    v16
  3. Start date: Jul 20, 2024 to Aug 20, 2024v15
  4. Start date: Jun 20, 2024 to Jul 20, 2024
    • Primary completion date: Mar 17, 2027 to Aug 31, 2027
    • Study completion date: Jul 30, 2027 to Sep 30, 2027
    v14
  5. Primary completion date: Mar 2028 to Mar 17, 2027
    • Study completion date: Apr 2028 to Jul 30, 2027
    • Start date: May 2024 to Jun 20, 2024
    v13
  6. Primary completion date: Feb 2028 to Mar 2028
    • Study completion date: Mar 2028 to Apr 2028
    • Start date: Apr 2024 to May 2024
    v12
  7. Secondary endpoints: details revised at 1 of 7 entries
    • Site contact updated
    v11
  8. Secondary endpoints: details revised at 2 of 7 entriesv10
  9. Eligibility criteria expanded, about 12 words
    • Secondary endpoints revised (7)
    • Study title revised
    v9
  10. Primary endpoint revised
    • Secondary endpoints: 5 to 7
    v8
  11. Trial status: Not Yet Recruiting to Recruitingv7 Show 4 more changesShow less
    • Start date: Jan 2024 to Apr 2024
    • Primary completion date: Nov 2027 to Feb 2028
    • Study completion date: Dec 2027 to Mar 2028
    • Site details revised
  12. Start date: Oct 2023 to Jan 2024
    • Primary completion date: Sep 2027 to Nov 2027
    • Study completion date: Oct 2027 to Dec 2027
    v6
  13. Start date: Aug 2023 to Oct 2023
    • Primary completion date: Aug 2027 to Sep 2027
    • Study completion date: Sep 2027 to Oct 2027
    v5
  14. Study title revisedv4
  15. Eligibility criteria expanded, about 64 words
    • Secondary endpoints revised (5)
    v3
  16. Start date: Oct 2022 to Aug 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test whether low-dose buprenorphine initiation for treatment of opioid use disorder is safe and effective.
Trial Details
NCT Number NCT05450718
Lead Sponsor Montefiore Medical Center
Collaborators: National Institute on Drug Abuse (NIDA)
Conditions
(from sponsor)		 Opioid Use Disorder
Related terms Opioid-Related Disorders
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov